---
title: "GMAB.US (GMAB.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GMAB.US/news.md"
symbol: "GMAB.US"
name: "GMAB.US"
parent: "https://longbridge.com/en/quote/GMAB.US.md"
datetime: "2026-05-07T18:07:05.942Z"
locales:
  - [en](https://longbridge.com/en/quote/GMAB.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GMAB.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GMAB.US/news.md)
---

# GMAB.US (GMAB.US) — Related News

### [Genmab Posts Strong Q1 2026 Revenue Growth and Highlights FDA Label Change for EPKINLY](https://longbridge.com/en/news/285581260.md)
*2026-05-07T15:27:15.000Z*
> Genmab reported a 25% year-on-year revenue growth in Q1 2026, reaching $896 million, driven by increased royalties and s

### [Genmab Q1 FY26 operating profit slips to $180 million; revenue climbs 25% to $896 million](https://longbridge.com/en/news/285576452.md)
*2026-05-07T15:03:20.000Z*
> Genmab reported a 25% increase in revenue to $896 million for Q1 FY26, while operating profit decreased to $180 million 

### [Genmab Updates Articles of Association to Expand Capital-Raising and Incentive Flexibility](https://longbridge.com/en/news/283180866.md)
*2026-04-17T16:50:52.000Z*
> Genmab A/S has updated its Articles of Association to enhance capital-raising and employee incentive flexibility. The co

### [Genmab A/S Share Capital Reduction](https://longbridge.com/en/news/283166320.md)
*2026-04-17T14:56:00.000Z*
> Genmab A/S has announced a reduction in its share capital by DKK 1,900,000, following a decision made at the Annual Gene

### [Genmab A/S (OTCMKTS:GNMSF) Trading Down 5.9%  - What's Next?](https://longbridge.com/en/news/282886854.md)
*2026-04-15T18:46:45.000Z*
> Genmab A/S (OTCMKTS:GNMSF) shares fell 5.9% to $280.85, with trading volume down 87% from average levels. The company re

### [Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer | GMAB Stock News](https://longbridge.com/en/news/282553850.md)
*2026-04-13T05:35:46.000Z*
> Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advance

### [Genmab Discloses Orbis as New 5% Major Shareholder](https://longbridge.com/en/news/281419643.md)
*2026-04-01T20:02:29.000Z*
> Genmab A/S announced that Orbis Investment Management Limited has become a major shareholder, holding 5.01% of the compa

### [This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday](https://longbridge.com/en/news/280802938.md)
*2026-03-27T13:32:47.000Z*
> Top Wall Street analysts have initiated coverage on several stocks with bullish ratings. BTIG's Gregory Lewis rated Iper